1Janet M. Finlay,Michael J. Zigmond. The Effects of Stress on Central Dopaminergic Neurons: Possible Clinical Implications[J] 1997,Neurochemical Research(11):1387～1394
4[11]Playfer J R.Parkinson's disease[J].Postgraduate Medical Journal,1997(859):257.
5[3]Andreasen NC,Olsen S.Negative vs positive schizophrenia definition and validation[J].Arch Gan Psychiatry,1982,39(4):789.
6[5]Raedler TJ,Jahn H,Arlt J,et al Adjunctive use of reboxetine in schizophrenia[J].Eur Psychiatry,2004,19(6):366-369.
7[8]Poyurovsky M,Isaacs I,Fuchs C,et al.Attenuation of olanzapine-induced weight gain with reboxetine in paints with schizophrenia:a Double-blind,placebo-controlled study[J].Am J Psychiatry,2003,160(2):297-302.
8[11]Linner L,Wiker C,Wadenberg ML,et al Noradrenaline reuptake inhibition enhances the antipsychofic-fike effect of raclopride and potentiates D2-blockage-inducod dopamine release in the medial prefrontal cortex of the rat[J].Neuropsychopharmscology,2002,27 (5):691-698.
9Shafer R A, Levant B. The D3 dopamine receptor in cellular and organismal function[J]. Psychopharmacology, 1998, 135:1-16.
10Childress A R, O'Brien C P. Dopamine receptor partial agonists could address the duality of cocaine craving[J]. Trends Pharmacol Sci,2000,21:6-9.
